| Name | Title | Contact Details |
|---|---|---|
Betty Wu |
VP, D&M Project Management and Customer Service | Profile |
Robin Shinkle |
Executive Director, IT Service Management & Delivery | Profile |
Carmine Dipietro |
Senior Director, Information Technology | Profile |
Gil Valadez |
Chief Operating Officer | Profile |
Lee Williams |
VP, Corporate Engineering, Ajinomoto Bio-Pharma Services | Profile |
Liberty BioSecurity’s multi-disciplinary research teams transform life science discoveries into global-class, industry leading solutions.
SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases. The Company has a robust kinase platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases. This vast resource empowers SLC’s scientists to identify novel drug candidates against kinase targets of interest. Another key part of SLC’s kinase drug development platform is KineCore, a kinase focused small molecule library that was designed and assembled in-house.
Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
MindMaze is pioneering a breakthrough computing platform that captures brain activity upon intent, creating a new operating system for computers - a brain O/S - with initial applications in the healthcare and gaming industries.